Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Active, not recruiting · NCT02881242 · Registry updated 2023-05-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, hormone-resistant prostate carcinoma, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2023-05-01 | NCT02881242 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jonsson Comprehensive Cancer Center | 115 |
| Novartis | 114 |
| Prostate Cancer Foundation | 24 |
| Stand Up To Cancer | 20 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | United States | 126 |